Editas Medicine, Inc. (EDIT)
2.87
-0.03
(-1.03%)
USD |
NASDAQ |
Oct 12, 09:56
Editas Medicine Free Cash Flow (Quarterly) : -29.67M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -29.67M |
| March 31, 2026 | -23.15M |
| December 31, 2025 | -36.45M |
| September 30, 2025 | -31.28M |
| June 30, 2025 | -50.21M |
| March 31, 2025 | -47.91M |
| December 31, 2024 | -51.30M |
| September 30, 2024 | -55.51M |
| June 30, 2024 | -60.56M |
| March 31, 2024 | -51.74M |
| December 31, 2023 | -23.55M |
| September 30, 2023 | -35.70M |
| June 30, 2023 | -40.04M |
| March 31, 2023 | -37.61M |
| December 31, 2022 | -42.90M |
| September 30, 2022 | -48.62M |
| June 30, 2022 | -38.48M |
| March 31, 2022 | -51.48M |
| December 31, 2021 | -37.43M |
| September 30, 2021 | -43.13M |
| June 30, 2021 | -41.66M |
| March 31, 2021 | -49.56M |
| December 31, 2020 | -41.48M |
| Date | Value |
|---|---|
| September 30, 2020 | -56.59M |
| June 30, 2020 | -32.70M |
| March 31, 2020 | -56.24M |
| December 31, 2019 | 39.33M |
| September 30, 2019 | -29.13M |
| June 30, 2019 | -27.32M |
| March 31, 2019 | -29.72M |
| December 31, 2018 | -0.088M |
| September 30, 2018 | -8.779M |
| June 30, 2018 | -18.12M |
| March 31, 2018 | -23.47M |
| December 31, 2017 | -25.36M |
| September 30, 2017 | -28.73M |
| June 30, 2017 | -26.52M |
| March 31, 2017 | 69.14M |
| December 31, 2016 | -14.03M |
| September 30, 2016 | -17.75M |
| June 30, 2016 | -11.06M |
| March 31, 2016 | -10.57M |
| December 31, 2015 | -8.369M |
| September 30, 2015 | -12.13M |
| June 30, 2015 | 19.91M |
| March 31, 2015 | -6.248M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | -107.91M |
| Geron Corp. | -16.05M |
| Halozyme Therapeutics, Inc. | 236.72M |
| Novavax, Inc. | -73.40M |
| AVITA Medical, Inc. | -3.742M |